Inclisiran

http://dbpedia.org/resource/Inclisiran an entity of type: Thing

Inclisiran (Handelsname Leqvio) ist ein Arzneistoff zur Behandlung erhöhter Cholesterinspiegel (Hypercholesterinämie) oder der gemischten Dyslipidämie (Fettstoffwechselstörung einhergehend mit zu hohen Spiegeln von Lipiden wie Cholesterin und Triglyzeriden oder beidem). Es gehört zur Gruppe der RNAi-Therapeutika. rdf:langString
L'inclisiran est un petit ARN interférent dirigé contre l'ARN du PCSK9, en cours de test dans les hypercholestérolémies. rdf:langString
Inclisiran, commercializzato con il nome Leqvio, è un farmaco per la riduzione effiace e sostenuta nel tempo del colesterolo LDL. Inclisiran è indicato il trattamento della malattia cardiovascolare aterosclerotica e dell'ipercolesterolemia familiare eterozigote in aggiunta al controllo dietetico e a una statina o in alternativa alle statine laddove esse siano controindicate o non tollerate. Si tratta del primo siRNA che riduce la traduzione della proteina PCSK9. LEQVIO è commercializzato in Europa da Novartis. rdf:langString
Inclisiran, sold under the brand name Leqvio, is a medication for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9. rdf:langString
rdf:langString Inclisiran
rdf:langString Inclisiran
rdf:langString Inclisiran
rdf:langString Inclisiran
xsd:integer 55572620
xsd:integer 1107260491
rdf:langString AX16
rdf:langString secondary source-derived descriptions of the class of this agent, information on its discovery, and its mechanism of action
<nicaraguanCórdoba> 10.0
xsd:integer 520
xsd:integer 1639324
xsd:integer 176399
rdf:langString August 2022
rdf:langString DB14901
xsd:integer 21
xsd:integer 679
rdf:langString D11931
rdf:langString Rx-only
xsd:integer 175
xsd:integer 309
xsd:integer 43
xsd:integer 6
rdf:langString no
rdf:langString ALN-PCSsc, ALN-60212
rdf:langString Leqvio
rdf:langString UOW2C71PG5
rdf:langString Inclisiran (Handelsname Leqvio) ist ein Arzneistoff zur Behandlung erhöhter Cholesterinspiegel (Hypercholesterinämie) oder der gemischten Dyslipidämie (Fettstoffwechselstörung einhergehend mit zu hohen Spiegeln von Lipiden wie Cholesterin und Triglyzeriden oder beidem). Es gehört zur Gruppe der RNAi-Therapeutika.
rdf:langString Inclisiran, sold under the brand name Leqvio, is a medication for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9. Inclisiran was approved for use in the European Union in December 2020. In August 2021, it received NICE approval for use by the National Health Service in the UK. In December 2021, it was approved for medical use in the United States.
rdf:langString L'inclisiran est un petit ARN interférent dirigé contre l'ARN du PCSK9, en cours de test dans les hypercholestérolémies.
rdf:langString Inclisiran, commercializzato con il nome Leqvio, è un farmaco per la riduzione effiace e sostenuta nel tempo del colesterolo LDL. Inclisiran è indicato il trattamento della malattia cardiovascolare aterosclerotica e dell'ipercolesterolemia familiare eterozigote in aggiunta al controllo dietetico e a una statina o in alternativa alle statine laddove esse siano controindicate o non tollerate. Si tratta del primo siRNA che riduce la traduzione della proteina PCSK9. LEQVIO è commercializzato in Europa da Novartis.
rdf:langString Inclisiran
rdf:langString S4
rdf:langString Rx-only
rdf:langString Rx-only
rdf:langString B1
xsd:nonNegativeInteger 15831
rdf:langString Leqvio
xsd:string 1639324-58-5
xsd:string 176399
xsd:string DB14901
xsd:string UOW2C71PG5
xsd:string D11931

data from the linked data cloud